Acadia Pharmaceuticals Inc (ACAD) stock
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$17.83−0.49 (-2.67%)
Close on Nov 18, 2026Market cap $3.07BP/E 8.1Yield –
Acadia Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Acadia Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $86.37M, down 63.5% year over year. For fiscal 2025 it was $104.81M, down 54.6% from the year before. The highest annual figure on record is $230.79M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.81M | -54.6% |
| FY2024 | Dec 31, 2024 | $230.79M | – |
| FY2023 | Dec 31, 2023 | -$73.38M | – |
| FY2022 | Dec 31, 2022 | -$223.60M | – |
| FY2021 | Dec 31, 2021 | -$170.44M | – |
| FY2020 | Dec 31, 2020 | -$286.59M | – |
| FY2019 | Dec 31, 2019 | -$246.55M | – |
| FY2018 | Dec 31, 2018 | -$247.44M | – |
| FY2017 | Dec 31, 2017 | -$292.41M | – |
| FY2016 | Dec 31, 2016 | -$272.82M | – |
| FY2015 | Dec 31, 2015 | -$164.61M | – |
| FY2014 | Dec 31, 2014 | -$93.23M | – |
| FY2013 | Dec 31, 2013 | -$38.30M | – |
| FY2012 | Dec 31, 2012 | -$20.89M | – |
| FY2011 | Dec 31, 2011 | -$22.85M | -251.4% |
| FY2010 | Dec 31, 2010 | $15.09M | – |
| FY2009 | Dec 31, 2009 | -$45.47M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $37.84M | +16.9% |
| Q1 FY2026 | Mar 31, 2026 | -$4.62M | -123.9% |
| Q4 FY2025 | Dec 31, 2025 | $17.39M | -88.7% |
| Q3 FY2025 | Sep 30, 2025 | $35.76M | +13.0% |
| Q2 FY2025 | Jun 30, 2025 | $32.37M | +6.4% |
| Q1 FY2025 | Mar 31, 2025 | $19.29M | +26.8% |
| Q4 FY2024 | Dec 31, 2024 | $153.50M | +339.3% |
| Q3 FY2024 | Sep 30, 2024 | $31.64M | – |
| Q2 FY2024 | Jun 30, 2024 | $30.44M | +902.2% |
| Q1 FY2024 | Mar 31, 2024 | $15.21M | – |
| Q4 FY2023 | Dec 31, 2023 | $34.94M | – |
| Q3 FY2023 | Sep 30, 2023 | -$57.78M | – |
| Q2 FY2023 | Jun 30, 2023 | $3.04M | – |
| Q1 FY2023 | Mar 31, 2023 | -$53.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$46.06M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$33.65M | – |
| Q1 FY2022 | Mar 31, 2022 | -$113.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$44.66M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.30M | – |
| Q2 FY2021 | Jun 30, 2021 | -$43.71M | – |
| Q1 FY2021 | Mar 31, 2021 | -$66.77M | – |
| Q4 FY2020 | Dec 31, 2020 | -$67.16M | – |
| Q3 FY2020 | Sep 30, 2020 | -$85.90M | – |
| Q2 FY2020 | Jun 30, 2020 | -$44.01M | – |
| Q1 FY2020 | Mar 31, 2020 | -$89.52M | – |
| Q4 FY2019 | Dec 31, 2019 | -$56.40M | – |
| Q3 FY2019 | Sep 30, 2019 | -$45.42M | – |
| Q2 FY2019 | Jun 30, 2019 | -$57.09M | – |
| Q1 FY2019 | Mar 31, 2019 | -$87.63M | – |
| Q4 FY2018 | Dec 31, 2018 | -$67.28M | – |
| Q3 FY2018 | Sep 30, 2018 | -$61.27M | – |
| Q2 FY2018 | Jun 30, 2018 | -$64.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$54.82M | – |
| Q4 FY2017 | Dec 31, 2017 | -$70.01M | – |
| Q3 FY2017 | Sep 30, 2017 | -$65.64M | – |
| Q2 FY2017 | Jun 30, 2017 | -$68.04M | – |
| Q1 FY2017 | Mar 31, 2017 | -$88.72M | – |
| Q4 FY2016 | Dec 31, 2016 | -$78.23M | – |
| Q3 FY2016 | Sep 30, 2016 | -$72.40M | – |
See a number that looks wrong?